Life Science Nation Newsletter | March 21, 2019 | Issue 309


  The LSN Story   |   Investor Platform   |   Company Platform   |   RESI Conference   |   Fundraising Consulting
   Life Science Investor Mandates
(Mar. 14 - Mar. 20 )
Focuses On New Treatments For Eye Diseases and Cancer
Invests in Clinical-Stage Therapeutics and Diagnostics
Raises New Fund For Platform Technologies
Invests Opportunistically In Life Science Deals
News
LSN Services
LSN Videos
LSN Media Partners
By Dennis Ford, Founder & CEO, Life Science Nation; Creator of RESI Conference Series

On March 25th, LSN will hold the inaugural RESI Europe life science partnering conference. Please review the program guide below, which showcases the dozens of senior investors speaking on RESI's panels, and the startup finalists who are bringing their novel technologies to RESI's Innovation Challenge and Pitch Challenge.

RESI is a dedicated early stage investor and channel partner conference.  The event is cross silo, and brings together investors and strategic partners seeking drugs, devices, diagnostics, and digitals health technologies. RESI is unique in that we have a one-to-one investor to fundraising CEO dynamic.

If you want to participate in the first ever RESI Europe, there's still time to register online and participate in RESI Partnering. We are looking forward to seeing you in Vienna on Monday...


By Claire Jeong, Director of Research, Asia BD, LSN

Our next RESI will be landing in Vienna in just 4 days, and we are excited to announce the 5 Europe Innovators' Pitch Challenge finalists for our inaugural Europe conference! These early-stage companies have been selected to present a short pitch to a panel of investor judges, who will provide these companies with constructive feedback.  

First introduced in RESI Boston last year (September 2018), the Pitch Challenge has become a unique opportunity for the earliest stage companies, especially those who have had minimal experience in pitching and getting in front of investors. By hearing from investors and key industry partners who actively source and evaluate early-stage technologies, companies are able to improve on their pitches and work on areas of improvement more efficiently.

The Europe Innovators' Pitch Challenge will run from 1:00 - 2:30 pm on the day of RESI and all attendees are welcome to participate as part of the audience. We look forward to seeing you there!

Moderated by Greg Mannix, VP of International Business Development at Life Science Nation, the investor panelists are:
  • Iris Öhrn, Investment Advisor - Life Sciences & Healthcare, Business Region Göteborg AB
  • Benedikt Luhmann, Principal, VI Partners
  • Andreas Jurgeit, Partner, Lundbeckfonden Emerge
  • Evan Castiglia, Principal, Philips Health Technology Ventures

RESI Europe Innovators Pitch Challenge Finalists

By Karen Deyo, Investor Research Analyst, LSN

Despite the relatively short span of time digital health, as a sector, has been in existence, there has been an explosion in technology and applications in recent years. The increase in digital applications and services, for providers, payers and consumers, is so pronounced, that governments are scrambling to keep up and provide some sort of regulatory framework that can apply to these cutting-edge technologies. From patient disease management to AI-powered diagnostics to EHR management to care coordination, the diversity within digital health can make it difficult to speak to the sector as a whole.

Addressing some of these questions at RESI Europe, the speakers on the Digital Health Investors panel will share their expertise in this area. The panel will take place from 9:00-9:50 AM, and we recommend that anyone interested in an investor's perspective on the field of digital health attend!

Moderator: Jonas Jendi (Investment Manager, Industrifonden)

  • Lara Koole (Principal, Philips Health Technology Ventures)
  • Tony Chang (Associate, M Ventures)
  • Thomas Walbert (Digital Health Innovation Manager, weXelerate)
  • Stephen Kearney (Innovation - Life & Health, Hannover Re)

Created & Produced by